Form 4: Cormorant Asset Management Sells 1.8 Million Shares of OnKure Therapeutics (OKUR)
SEC Form 4
Cormorant Asset Management, along with related entities and Bihua Chen, reported the sale of 1,813,439 shares of OnKure Therapeutics Class A Common Stock at an average price of $1.8545 per share.
Summary
- Cormorant Asset Management, LP, along with several related entities including Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare Fund IV, LP, Cormorant Private Healthcare Fund V, LP, and Bihua Chen, filed a Form 4.
- The filing reports the sale of 1,813,439 shares of OnKure Therapeutics, Inc. (OKUR) Class A Common Stock on May 15, 2025.
- The shares were sold in a series of open market transactions with prices ranging from $1.85 to $2.03 per share, resulting in a weighted average sale price of $1.8545.
- Cormorant Asset Management, LP acts as the investment manager for the various Cormorant Healthcare Funds.
- Bihua Chen serves as the managing member of the general partners for these funds and the general partner of Cormorant Asset Management, LP.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock sales. The sale itself doesn't necessarily indicate a positive or negative outlook for the company.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders or major shareholders of a publicly traded company buy or sell the company's stock. This filing indicates a change in ownership by a significant shareholder, which can be of interest to other investors.
Stakeholder Impact
- The sale of a significant number of shares by a major shareholder like Cormorant Asset Management could potentially influence the market's perception of OnKure Therapeutics.
- Existing shareholders may react to this news, potentially leading to price fluctuations.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Date of transaction: Sale of Class A Common Stock |
| 05/19/2025 | Date of Form 4 filing |
Keywords
Form 4, OnKure Therapeutics, OKUR, Cormorant Asset Management, Bihua Chen, Share Sale, Class A Common Stock, Investment Manager, Healthcare Funds
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.